<![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>

Advertisement News|Articles|May 6, 2026 Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer Author(s)Ashling Wahner Fact checked by: Chris Ryan Listen0:00 / 0:00 Key Takeaways DESTINY-Breast11 randomized high-risk HER2-positive early breast cancer to T-DXd→THP, ddAC→THP, or T-DXd monotherapy; the monotherapy arm closed early per IDMC recommendation. RCB-0/RCB-I reached 81.3% with T-DXd→THP versus 69.1% with ddAC→THP, with RCB-0 rates of 68.8% and 57.5%, respectively. RCB distribution significantly shifted from RCB-II toward RCB-0/RCB-I with T-DXd→THP (nominal P = .0059), and median RCB among non-pCR patients improved (1.5 vs 1.7). Subgroup consistency was observed across age, region, hormone receptor status, stage, and nodal status, including higher RCB-0/RCB-I in HR-positive (78.0% vs 64.7%) and HR-negative disease (90.4% vs 81.2%). Investigators noted concordance with prior pCR findings (67.3% vs 56.3%; P = .003) and reported a more favorable toxicity profile for the T-DXd→THP regimen.SHOW MORE Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer. Advertisement Neoadjuvant treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) followed by paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) reduced the extent of residual cancer burden (RCB) compared with dose-dense doxorubicin and cyclophosphamide (ddAC) followed by THP (ddAC-THP) in patients with high-risk, HER2-positive early-stage breast cancer, according to findings from an analysis of the phase 3 DESTINY-Breast11 trial (NCT05113251) presented at the 2026 ESMO Breast Cancer Congress.1The combined rate of RCB-0 and RCB-I, which are validated predictors of favorable long-term survival, was 81.3% with the T-DXd–containing regimen (n = 321) vs 69.1% with the comparator regimen (n = 320), with improvements observed across all prespecified patient subgroups. The RCB-0 rates were 68.8% and 57.5%, respectively.“These results indicate that T-DXd/THP benefitted even patients who have not achieved a pathologic complete response [pCR], and this pattern of RCB shift in previous trials was strongly associated with subsequent improvements in recurrence-free survival,” lead study author Lajos Pusztai, MD, DPhil, said to OncLive®.Pusztai is a professor of medicine (Medical Oncology) at the Yale School of Medicine, as well as co-leader of Genetics, Genomics and Epigenetics at Yale Cancer Center in New Haven, Connecticut.What was the design of the DESTINY-Breast11 trial?This randomized, global, multicenter, open-label trial enrolled patients at least 18 years of age with previously untreated HER2-positive early breast cancer and confirmed high-risk status, defined as clinical stage T3 and N0 to N3, T0 to T4 and N1 to N3, or inflammatory breast cancer.Patients were randomly assigned 1:1:1 to receive 1 of 3 neoadjuvant regimens:T-DXd for 4 cycles, followed by THP for 4 cyclesddAC for 4 cycles, followed by THP for 4 cyclesT-DXd monotherapy for 8 cycles (this arm was closed early following an independent data monitoring committee recommendation)The primary end point was pCR rate following surgery as assessed by blinded central review. Secondary end points included event-free survival (EFS), safety, overall survival, and health-related quality of life.What key efficacy findings from DESTINY-Breast11 have been previously reported?Data presented at the 2025 ESMO Congress showed that the pCR rate was 67.3% in the T-DXd/THP arm (n = 321) compared with 56.3% in the ddAC-THP arm (n = 320), representing a statistically significant and clinically meaningful improvement of 11.2% (95% CI, 4.0%-18.3%; P = .003).2 Among patients with hormone receptor–positive disease, the pCR rates in these respective arms were 61.4% (n = 236) vs 52.3% (n = 235; difference, 9.1%; 95% CI, 0.2%-17.9%). In those with hormone receptor–negative disease, the pCR rates were 83.1% (n = 83) and 67.1% (n = 85), respectively (difference, 16.1%; 95% CI, 3.0%-28.8%).How was RCB evaluated in DESTINY-Breast11?The RCB index provides a continuous, quantitative measure of residual invasive disease in the breast and axillary nodes after neoadjuvant chemotherapy.1 Patients were categorized into 4 classes based on validated cut-off values: RCB-0 (equivalent to pCR), RCB-I (minimal residual disease), RCB-II (moderate residual disease), and RCB-III (extensive residual disease). Lower RCB scores have been associated with meaningful EFS benefit, regardless of hormone receptor status.What were additional key findings from the DESTINY-Breast11 RCB analysis?The distribution of the RCB index showed a significant shift from the RCB-II class toward RCB-0 and RCB-I with T-DXd followed by THP compared with ddAC-THP (nominal P = .0059). Among patients who did not achieve a pCR (RCB > 0), the median RCB index was lower in the T-DXd/THP group at 1.5 compared with 1.7 in the ddAC-THP group.The rate of RCB-II disease was reduced from 18.8% in the ddAC-THP arm to 10.6% in the T-DXd/THP arm, whereas RCB-III rates were 4.7% and 4.0% for ddAC-THP and T-DXd/THP, respectively. Consistent improvements in the combined RCB-0/I rates were observed with T-DXd followed by THP across all prespecified subgroups, including:Age and geographical region: Benefits were consistent in patients younger and older than 65 years of age and across Asia, Europe, and North AmericaHormone receptor status: In the T-DXd/THP arm, the combined RCB-0/I rate was 78.0% for patients with hormone receptor–positive disease and 90.4% for those with hormone receptor–negative disease, compared with 64.7% and 81.2% in the ddAC-THP arm, respectively.Disease stage: In the T-DXd/THP arm, the combined RCB-0/I rate was 83.6% for patients with stage II disease and 78.9% for those with stage III disease, compared with 71.7% and 66.0% in the ddAC-THP arm, respectively.Nodal stage: In the T-DXd/THP arm, the combined RCB-0/I rate was 80.8% for patients with node-negative disease and 81.5% for those with node-positive disease, compared with 68.9% and 69.8% in the ddAC-THP arm, respectively.“The most important message from the RCB analysis is that T-DXd/THP has shifted the RCB distribution to lower values across the entire range,” Pusztai concluded. “Even patients who had residual cancer after the neoadjuvant therapy had smaller residual cancers if they received T-DXD/THP. This is important because the extent of residual cancer among those who do not achieve pCR is highly prognostic.”Disclosures: Pusztai reported receiving consulting fees and honoraria for advisory board participation from AstraZeneca, Pfizer, Merck, Bristol-Myers Squibb, Menarini-Stemline, BeOne, Personalis, Natera, Agendia, Exact Sciences, and Radionetics; receiving institutional research funding from Pfizer, AstraZeneca, Merck, Menarini-Stemline, Radionetics, and Exact Sciences; and having stock ownership in Fourion Inc and stock options in Ataraxis.ReferencesPusztai L, Harbeck N, Boileau J, et al. Residual cancer burden (RCB) following neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in highrisk HER2+ early-stage breast cancer (eBC). Presented at: 2025 ESMO Breast Cancer Congress. May 6-8, 2026; Berlin, Germany. Abstract LBA1.Harbeck N, Modi S, Pusztai L, et al. DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Ann Oncol. 2025;36(suppl 2):S302-S303. doi:10.1016/j.annonc.2025.08.720 NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementMANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ByCourtney FlahertyMay 6th 2026Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaByAjai Chari, MDMay 6th 2026FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLCByCaroline SeymourMay 6th 2026Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and DiscoveryByHuntsman Cancer InstituteMay 6th 2026ASCO 2026 Breast Cancer Preview: Read up on the Insights to Know Before You Go ByAshling Wahner May 6th 2026 Latest CMEVirtual EventMissouri Oncology Society1 Session is Available!View moreVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView more Advertisement Advertisement Trending on OncLive1ASCO 2026 Breast Cancer Preview: Read up on the Insights to Know Before You Go 2FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC3Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer4Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management5Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery